title: The indicator of hypoxia in acute leukemia: Ischemia-modified albumin.
abstract: BACKGROUND
  Hypoxia plays an important role in the development and progression of hematologic malignancies.
  
  
  OBJECTIVE
  This study was intended to investigate the effectiveness of ischemia-modified albumin (IMA) for demonstrating hypoxia in patients with acute leukemia.
  
  
  METHODS
  Blood specimens were collected from 132 subjects (44 acute leukemia patients, 40 iron deficiency anemia (IDA) patients and 48 healthy controls). Serum levels of IMA and malondialdehyde (MDA) were analyzed using conventional methods.
  
  
  RESULTS
  Serum levels of IMA were higher in patients with acute leukemia than in those with IDA and healthy controls (acute leukemia patients; 0.69 ± 0.14 ABSUs, IDA patients; 0.61 ± 0.09 ABSUs, controls; 0.50 ± 0.09 ABSUs, respectively). There was a negative correlation between serum IMA levels and hemoglobin (Hb) values (r = - 0.312) and between serum IMA levels and hematocrit (Hct) values, (r = - 0.305) in patients with acute leukemia. Serum levels of MDA were higher in patients with acute leukemia than in those with IDA. But there was no difference in patients with acute leukemia and IDA compared to healthy controls (acute leukemia patients; 2.23 ± 1.82 nmol/mL, IDA patients; 1.36 ± 0.94 nmol/mL, healthy controls; 1.79 ± 0.78 nmol/mL, respectively).
  
  
  CONCLUSIONS
  IMA can be effective for demonstrating hypoxia in patients with acute leukemia.
authors.affiliation: Department of Hematology, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey.|Department of Hematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Nergiz
authors.initials: N
authors.lastname: Erkut
authors.affiliation: Department of Medical Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Mentese
authors.affiliation: Department of Hematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Hasan Mucait
authors.initials: HM
authors.lastname: Ozbas
authors.affiliation: Department of Medical Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Aysegul
authors.initials: A
authors.lastname: Sumer
authors.affiliation: Department of Medical Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Asım
authors.initials: A
authors.lastname: Orem
authors.affiliation: Department of Public Health, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Topbas
authors.affiliation: Department of Hematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sonmez
mesh_terms: D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood* / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000097:blood* / Q000473:pathology; D007938:Leukemia / Q000097:blood* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D012709:Serum Albumin; D000075462:Serum Albumin, Human
chemical_list: D015415:Biomarkers; D006454:Hemoglobins; D012709:Serum Albumin; C561522:ischemia-modified albumin; D008315:Malondialdehyde; D000075462:Serum Albumin, Human
keywords: Ischemia-modified albumin; acute leukemia; hypoxia